Friday, May 17, 2013

Celebrating the life and work of Barbara Brenner

Last Friday, the world lost a powerful advocate for breast cancer awareness and research. Barbara Brenner passed away from complications of amyotrophic lateral sclerosis (ALS) on May 10, 2013. Ms. Brenner, a lawyer by training and a civil rights activist by design, was diagnosed with breast cancer at the age of 41, an experience that compelled her to become involved with what was then a fledgling grassroots advocacy organization in San Francisco, Breast Cancer Action (BCA)

Over the next twenty years, Ms. Brenner helped the organization grow into one of the most respected voices in a crowded advocacy field, and her powerful vision and leadership fundamentally shaped the discourse surrounding breast cancer. During her 15 year tenure as BCA’s executive director, Ms. Brenner worked to advance research on both prevention of and treatment for breast cancer, while speaking out against a system that was, in her opinion, driven by profit and politics.

Upon her diagnosis with ALS in 2010, Ms. Brenner started a blog, Healthy Barbs, to share her reflections on living with illness. In 2011, Ampersand was fortunate to have an opportunity to share a post from Ms. Brenner’s blog in which she illuminates the experience of participating in a clinical trial. In honor of her passion, moxie, and contributions as an advocate, we are pleased to repost that piece today.

Please read about Barbara's extraordinary life and life's work via the below post and the above-included links, and we hope that you will be as inspired as we were by these accounts.  If you are, thank you for doing whatever you can to keep her memory and mission alive.

That's why they call them "trials"
by Barbara Brenner

Given the times we seem to be in, maybe you’re thinking you’re about to read a blog about the trials and tribulations of Donald Trump, who can’t seem to tear himself away from the big bucks of an NBC contract to run for president, or the upcoming trial of Dominique Strauss-Kahn, managing director of the International Monetary Fund, on sexual assault charges, or the struggles of Maria Shriver, who turns out to have been married to another adulterous male politician.

While those topics are undoubtedly more fun to explore, they are not my subject today. I want to address the serious topic of drug clinical trials, a topic that most people who aren’t doctors—and, tragically, some who are—don’t understand.

What is a drug clinical trial? Clinical trials are used to advance scientific research into the treatment of illnesses.

A clinical trial is a medical research process used to determine if a drug is safe for humans to take and effective to treat the medical condition that it is intended to address. The drug under investigation—called the treatment—is compared to what is called a “control,” which is either a placebo (a pill or infusion that looks like the drug under investigation, but that has no biological properties) or an existing treatment for the condition, so that researchers can determine whether the drug under investigation is more effective than the alternative to which it’s being compared. The treatment group of patients and the control group of patients have to be balanced in number so that the results of the trial are meaningful.

Drug trials are necessary because without them, there is no way of knowing whether the treatment drug that is the subject of the trial will work for the patients in the trial.
Two other features of well-designed trials, randomization and blindness, are important to ensure that the trial reflects how the drug works, rather than a bias on the part of those administering the trial.

Randomization is the process by which patients in the trial are assigned to receive either the drug under investigation or the control. By assigning to patients at random, researchers avoid any bias that might creep into trial results by choosing, for example, the apparently healthier patients to receive the drug, or the less-healthy patients to receive the control.

Blindness refers to who knows what about which patients are in the treatment group or the control group. Ideally, drug trials are “double blind,” meaning that neither the researchers nor the patients know which group the patient is in. Double-blind trials keep researchers from making judgments about how patients are doing based on what they are known to be taking. They may also keep patients from deciding to drop out of trials because they didn’t get into the treatment group. (Open-label trials – where both the patients and the researchers know what drug is—have become much more common in breast cancer than double-blind trials.)

A drug trial is considered a success if the patients getting the treatment drug do better than patients in the control group by a statistically significant percentage. A successful trial tells nothing about whether the treatment drug actually worked in an individual patient. After all, it’s possible that the patient would have improved without the drug in question. Miracles do sometimes happen in medicine, and not necessarily because doctors make them happen.

Clinical trials in the abstract

I know a lot about clinical trials from my work as a breast cancer activist. From that work, I have come to believe that trials should demonstrate that the drug being tested can do at least one of three things before it is marketed to the public:
  • Improve survival
  • Improve quality of life
  • Cost less than existing, equally effective treatments
These ideas about the goals and structures of clinical trials are fine in the abstract. It’s harder when they have very personal implications, either for you or for someone you love. While no promises are ever made to patients entering clinical trials, it’s hard for the patients or the people who love them not to believe at some level that the drug under investigation will improve their lives. People often enter trials believing this, no matter what they are told about the purpose of the trial.

The personal side

That my friends share this belief was evident when I told them that I am being screened to see if I’m eligible to be in a clinical trial. Many have hoped that, if I was eligible for the trial, I would get the drug being investigated, not the control, which in this case is a placebo. That hope seems to convey the belief that the drug will work. Whether it will or not is, in fact, what the trial is intended to test.

I know that participating in a clinical trial means taking a chance that I won’t get the drug under investigation, as well as the chance that that drug won’t work anyway. I know that it’s impossible to know from a clinical trial whether the drug under investigation will help me, even if it shows benefit for a significant percentage of people in the trial.

At the same time, I know there is only one approved treatment for ALS, the disease I have. At best, that treatment only delays progression. Better treatments are needed: ones that will extend patients’ lives or improve the quality of the lives they live with this devastating illness. I know that only through clinical trials can better drugs be found, and I hope that this trial—and other trials—will advance the knowledge of what does and doesn’t work to treat ALS.

And I’ll also keep in mind, as I enter the trial that placebos also work sometimes.

The following piece was originally re-posted on Ampersand in 2011 from the blog, Healthy Barbs, with permission from Ms. Brenner. If you are interested in learning more about Ms. Brenner's work and life, we encourage you to read the transcript from her oral history, which is part of the Sophia Smith Collection at Smith College. 

No comments:

Post a Comment

We encourage you to share your thoughts on this post. To leave a comment, please select one of the options from the drop-down menu below. Most commenters choose “Name/URL,” and simply enter their name. A URL is not required. We looking forward to hearing from you!